Modality
Gene Therapy
MOA
PLK4i
Target
TNFα
Pathway
Incretin
MesoNarcolepsyEndometrial Ca
Development Pipeline
Preclinical
~Apr 2022
→ ~Jul 2023
Phase 1
~Oct 2023
→ ~Jan 2025
Phase 2
Apr 2025
Phase 2Current
NCT04638105
2,058 pts·Narcolepsy
2025-04→TBD·Not yet recruiting
2,058 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q2
P2
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04638105 | Phase 2 | Narcolepsy | Not yet recr... | 2058 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| VKT-4052 | Viking Therapeutics | Phase 2/3 | TNFα | |
| APG-2066 | Apogee Ther | Phase 2 | TNFα | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D |